

# Riociguat + Bosentan

# MFB 1299

Onderbouwend	Stof	Effect	Code
SPC Adempas	riociguat + bosentan	afname riociguatspiegel met 27% door bosentan bij PAH-patiënten	1A

Overig	Stof	Effect
SPC Adempas	riociguat + inductoren	combinatie met sterke CYP3A4-inductoren (bijv. fenytoïne, carbamazepine, fenobarbital of sint-janskruid) kan ook leiden tot lagere plasmaconcentraties van riociguat.
Prescribing Information USA Adempas <a href="http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf">http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf</a> , geraadpleegd 23-06-2015	riociguat + inductoren	moderate CYP3A inducers (bosentan): no dose adjustment. Strong inducers of CYP3A may significantly reduce riociguat exposure. Data are not available to guide dosing of riociguat when strong CYP3A inducers are co-administered.
SPC + Prescribing Information USA Adempas	riociguat	riociguat pharmacokinetics are dose proportional from 0.5 to 2.5 mg. Inter-individual variability of riociguat AUC across all doses is approximately 60%, and within-subject variability is approximately 30%.
EPAR Adempas	riociguat	the dose range between 1.0 mg and 2.5 mg covers the range from the minimum effective dose to the maximum tolerated dose in healthy volunteers based on the effects seen for heartrate, blood pressure and plasma renin activity. Dose titration is necessary in order to improve tolerability (e.g. hypotension) and also takes into consideration the large inter-individual variability in pharmacokinetics.

## Opmerkingen

WFG: alleen bewijs voor bosentan. Standaardlijst CYP3A4-inductoren niet koppelen, metabolisme gaat vooral via CYP1A1 en in mindere mate via CYP3A4.

Stockley, Hansten, Pubmed, [www.clinicaltrials.gov](http://www.clinicaltrials.gov): geen aanvullende informatie.

Overige inductoren: geen informatie.

Risicogroep	
-------------	--

	Interactie	Actie	Datum
Beslissing WFG	Ja	Nee	22 september 2015